Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 11/2009

01-11-2009 | Original Research Article

Cost Effectiveness of Facility-Based Care, Home-Based Care and Mobile Clinics for Provision of Antiretroviral Therapy in Uganda

Authors: Dr Joseph B. Babigumira, Ajay K. Sethi, Kathleen A. Smyth, Mendel E. Singer

Published in: PharmacoEconomics | Issue 11/2009

Login to get access

Abstract

Background: Stakeholders in HIV/AIDS care currently use different programmes for provision of antiretroviral therapy (ART) in Uganda. It is not known which of these represents the best value for money.
Objective: To compare the cost effectiveness of home-based care (HBC), facility-based care (FBC) and mobile clinic care (MCC) for provision of ART in Uganda.
Methods: Incremental cost-effectiveness analysis was performed using decision and Markov modeling of adult AIDS patients in WHO Clinical Stage 3 and 4 from the perspective of the Ugandan healthcare system. The main outcome measures were cost (year 2008 values), life expectancy in life-years (LY) and the incremental cost-effectiveness ratio (ICER) measured as cost per QALY or LY gained over 10 years.
Results: Ten-year mean undiscounted life expectancy was lowest for FBC (3.6 LY), followed by MCC (4.3 LY) and highest for HBC (5.3 LY), while the mean discounted QALYs were also lowest for FBC (2.3), followed by MCC (2.9) and highest for HBC (3.7). The 10-year mean costs per patient were lowest for FBC ($US3212), followed by MCC ($US4782) and highest for HBC ($US7033). The ICER was lower for MCC versus FBC ($US2241 per LY and $US2615 per QALY) than for HBC versus MCC ($US2251 per LY and $US2814 per QALY). FBC remained cost effective in univariate and probabilistic sensitivity analyses.
Conclusions: FBC appears to be the most cost-effective programme for provision of ART in Uganda. This analysis supports the implementation of FBC for scale-up and sustainability of ART in Uganda. HBC and MCC would be competitive only if there is increased access, increased adherence or reduced cost.
Literature
1.
2.
3.
Heltzer NE. Uganda’s early gains against HIV eroding. AIDS Read 2007; 17: 252
4.
5.
6.
Mermin J, Ekwaru JP, Liechty CA, et al. Effect of cotrimoxazole prophylaxis, antiretroviral therapy, and insecticide- treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006 Apr 15; 367 (9518): 1256–61PubMedCrossRef
7.
Shrestha RK, Marseille E, Kahn JG, et al. Cost-effectiveness of home-based chlorination and safe water storage in reducing diarrhea among HIV-affected households in rural Uganda. Am J Trop Med Hyg 2006 May; 74 (5): 884–90PubMed
8.
Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr 2007 Mar 1; 44 (3): 336–43PubMedCrossRef
9.
Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006 Nov 4; 368 (9547): 1587–94PubMedCrossRef
10.
Mermin J, Were W, Ekwaru JP, et al. Mortality in HIVinfected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008 Mar 1; 371 (9614): 752–9PubMedCrossRef
11.
Petitti D. Meta-analysis, decision analysis and costeffectiveness analysis. New York: Oxford University Press, 1994
12.
13.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 Oct-Dec; 13 (4): 322–38PubMedCrossRef
14.
Gold MR, Siegel JE, Russell LB, et al. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996
15.
16.
Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003 Mar 1; 361 (9359): 717–25PubMedCrossRef
17.
Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cote d’Ivoire. N Engl J Med 2006 Sep 14; 355 (11): 1141–53PubMedCrossRef
18.
19.
Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997 Jul 26; 350 (9073): 245–50PubMedCrossRef
20.
Badri M, Bekker LG, Orrell C, et al. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004 May 21; 18 (8): 1159–68PubMedCrossRef
21.
22.
Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002 May 3; 16 (7): 1051–8PubMedCrossRef
23.
Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002 May 1; 30 (1): 105–10
24.
Murray C, Lopez A, Ahmad OB, et al. World mortality in 2000: life tables for 191 countries. Geneva: WHO, 2002
25.
26.
Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002 Feb 1; 29 Suppl. 1: S2–10CrossRef
27.
Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care 2006 Oct; 44 (10): 893–9PubMedCrossRef
28.
Parruti G, Manzoli L, Toro PM, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006 Jan; 20 (1): 48–56PubMedCrossRef
29.
Data on file, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA, 2006
30.
Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002 Nov-Dec; 22 (6): 475–81PubMedCrossRef
31.
32.
Govender V, McIntyre D, Grimwood A, et al. The costs and perceived quality of care for people living with HIV/AIDS in the Western Cape Province in South Africa [small applied research no. 14]. Bethesda (MD): Partnerships for Health Reform, Abt Associates Inc., 2000 [online]. Available from URL: (http://​www.​abtassociates.​com/​reports/​12-sar14-4-2000.​pdf) [Accessed 2009 Aug 31]
33.
Data on file, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA, 2006
34.
Chandler R, Decker C, Nziyige B. Estimating the cost of providing home-based care for HIV/AIDS in Rwanda. Bethesda (MD): Partners for Health Reformplus, Abt Associates Inc., 2004
35.
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 May; 17 (5): 479–500PubMedCrossRef
36.
Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006 Dec; 44 (6): 1598–606PubMedCrossRef
37.
Data on file, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA, 2006
38.
Hansen K, Woelk G, Jackson H, et al. The cost of homebased care for HIV/AIDS patients in Zimbabwe. AIDS Care 1998 Dec; 10 (6): 751–9PubMedCrossRef
39.
Moalosi G, Floyd K, Phatshwane J, et al. Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients, Francistown, Botswana. Int J Tuberc Lung Dis 2003 Sep; 7 (9 Suppl. 1): S80–5
40.
Wasswa H. More than half of Ugandan AIDS patients dont get the drugs they need. BMJ 2008; 336 (7640): 348–9PubMedCrossRef
41.
National Budget Framework Paper, Budget Speech 2008/09. Ministry of Finance and Ministry of Health, Republic of Uganda
42.
Musgrove P, Fox-Rushby J. Cost-effectiveness analysis for priority setting. In: Jamison DT, editor. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press, 2006: 271–86
43.
Samb B, Celletti F, Holloway J, et al. Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med 2007 Dec 13; 357 (24): 2510–4PubMedCrossRef
Metadata
Title
Cost Effectiveness of Facility-Based Care, Home-Based Care and Mobile Clinics for Provision of Antiretroviral Therapy in Uganda
Authors
Dr Joseph B. Babigumira
Ajay K. Sethi
Kathleen A. Smyth
Mendel E. Singer
Publication date
01-11-2009
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 11/2009
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11318230-000000000-00000

Other articles of this Issue 11/2009

PharmacoEconomics 11/2009 Go to the issue

Review Article

Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region

Review Article

Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program

Editorial

Developing Nations Special Issue

Current Opinion

The Future of Health Technology Assessment in Healthcare Decision Making in Asia

Review Article

Cost Effectiveness in Low- and Middle-Income Countries

Original Research Article

Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries